Obstetrics & gynecology science

Korean Society of Obstetrics and Gynecology (대한산부인과학회)
권호 표지

Knowledge of human papillomavirus infection and acceptability of vaccination among adult women in Korea

우리나라 성인 여성의 HPV 감염과 HPV 백신 접종에 대한 지식 및 태도 조사

Choi, Kyoung-A;Kim, Jung-Hye;Lee, Kyoung-Soon;Oh, Jin-Kyoung;Liu, Shan-Ni;Shin, Hai-Rim
최경아;김정혜;이경순;오진경;유선니;신해림

  • Published : 2008.06.15
⟨ Previous Next ⟩

Abstract

=목적: HPV 예방 백신은 성생활을 시작 전인 청소년기에 접종이 이루어져야 하고, 부모와 가족들에 의해 영향을 받을 것이다. 본 연구는 19세 이상 성인을 대상으로 하여 HPV 감염에 대한 지식 및 백신에 대한 태도를 조사하였다.방법: 2006년 8월부터 2007년 11월까지 부산 일신기독병원 산부인과를 방문한 여성 957명을 대상으로 설문 조사를 하였다. HPV 예방 접종의 수용도, HPV 감염에 대한 인지된 감수성, 인지된 질병의 심각성, 백신 접종에 대한 인지된 혜택, 백신 접종에 대한 인지된 장애 및 중재의 내용을 설문 문항으로 구성하였다.결과: 설문에 응답한 여성 957명의 평균 연령은 40세였다. HPV 감염이 자궁경부암과 관련이 있다는 사실을 알고 있는 경우가 23.8%였다. 그러나 HPV 예방 백신으로 자궁경부암 예방이 가능하다면 78.3%가 HPV 예방 백신을 접종 받겠다고 응답하였다. 접종을 희망하지 않은 경우에는 고가의 비용과 부작용이 주된 이유였다.

Keywords

References

  1. Piasani P, Parkin DM, Munoz N, Ferlay J. Cancer and infection: estimates of attributable fraction in 1990. Cancer Epidermiol Biomarkers and Prev 1997; 6: 387-400
  2. Sankaranarayanan R, Black RJ, Swaminathan R, Parkin DM. An overview of cancer survival in developing countries. IARC Sci Publ 1998; 145: 135-73
  3. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancer in 1990. Int J cancer 1999; 80: 827-41 https://doi.org/10.1002/(SICI)1097-0215(19990315)80:6<827::AID-IJC6>3.0.CO;2-P
  4. Berkow R, Merck Research Laboratories. The Merck manual of Medical information. Whitehouse station, NJ: Merck Research Laboratories; 1997
  5. Shin HR, Jung KW, Won YJ, Park JG, 139 KCCR-afffiliated hospital. 2002 Annual Report of the Korea central cancer Registry: Based on registered data from 139 hospitals. Cancer Res Treat 2004; 36: 103-14 https://doi.org/10.4143/crt.2004.36.2.103
  6. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-65 https://doi.org/10.1136/jcp.55.4.244
  7. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study Group. J Natl Cancer Inst 1995; 87: 796-802 https://doi.org/10.1093/jnci/87.11.796
  8. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-9 https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
  9. Bergeron C, Barrasso R, Bcandenon S, Flamant P, Croissant O, Orth G. Human papillomaviruses associated with cervical intraepithelial neoplasia. Great diversity and distinct distribution in lowand high- grade lesion. Am J surg pathol 1992; 16: 641-9 https://doi.org/10.1097/00000478-199207000-00002
  10. Lungu O, Sun XW, Felix J, Richart RM, Silverstein S, Wright TC Jr. Relationship of human papillomavirus type to grade of cervical intraepithelial neoplasia. JAMA 1992; 267: 2493- 6 https://doi.org/10.1001/jama.267.18.2493
  11. Kim CJ, Kim BG, Kim SC, Kim YT, Kim YM, Park SY, et al. Sexual behavior of Korean young women; preliminary study for introducing of HPV prophylactic vaccine. Korean J Gynecol Oncol 2007; 18: 209-18
  12. Stratton KR, Durch J, Lawrence RS, Institute of Medicine (U.S.). Committee to Study Priorities for Vaccine Development. Vaccines for the 21st century : a tool for decisionmaking. Washington, DC : National Academy Press; 2000
  13. Garnertt GP, Dubin G, Slaoui M, Darcis T. The potential epidermiological impact of a genital herpes vaccine for women. Sex Transm Infect 2004; 80: 24-9 https://doi.org/10.1136/sti.2002.003848
  14. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004; 10: 1915-23 https://doi.org/10.3201/eid1011.040222
  15. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, et al. Projected clinical benefits and cost-effectivemess of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96: 604-15 https://doi.org/10.1093/jnci/djh104
  16. Zimet GD, Mays RM, Fortenberry JD. Vaccines against sexually transmitted infections: promise and problems of the magic bullets for prevention and control. Sex Transm Dis 2000; 27: 49-52 https://doi.org/10.1097/00007435-200001000-00010
  17. Han YJ, Lee SR, Kang EJ, Kim MK, Kim NH, Kim HJ, et al. Knowledge regarding cervical cancer, human papillomavirus and future acceptance of vaccination among girls in their late teens in Korea. Kor J Obstet Gynecol. 2007; 50: 1090-9
  18. Glanz K, Rimer BH, Lewis FM. Health behavior and health education : theory, research, and practice. 3rd ed. San Francisco: Jossey-Bass: 2002
  19. zur Hausen H. Are human papillonavirus infections not necessary or sufficient causal factors for invasive cancer of the cervix? Int J cancer 1995; 63: 315-6 https://doi.org/10.1002/ijc.2910630228
  20. Syrjanen KJ. Spontaneous evolution of intraepithelial lesions according to the grade and type of implicated human papillomavirus (HPV). Eur J Obstet Gynecol Reprod Biol 1996; 65: 45-53 https://doi.org/10.1016/0028-2243(95)02303-A
  21. Joo WD, Kim SH, Kim DY, Suh DS, Kim YM. Prevalence of human papillomavirus infection in Korea women: risks of abnormal pap smears and cervical neoplasia. Kor J Gynecol Oncol 2004; 15: 309-16
  22. Brown DR, Shew ML, Qudadri B, Neptune N, Vargas M, Tu W, et al. A longitudinal study of genital human papillomavirus infection in cohort of closely followed adolescent women. J Infect Dis 2005; 191: 182-92 https://doi.org/10.1086/426867
  23. Baseman JG, Kousky LA. The epidermiology of human papillomavirus infections. J Clin Virol 2005; 32 Suppl 1: S16-24 https://doi.org/10.1016/j.jcv.2004.12.008
  24. Bekkers RL, Massuger LF, Bulten J, Melchers WJ. Epidermiological and clinical aspects of human papillomavirus defection in the prevention of cervical cancer. Rev Med Virol 2004; 14: 95-105 https://doi.org/10.1002/rmv.416
  25. Harper DM. Why am I scared of HPV? CA Cancer J Clin 2004; 54: 245-7. https://doi.org/10.3322/canjclin.54.5.245
  26. Colmbo N. The wider impact on women's health. More than cervical cancer? Eur J Obstet Gynecol Reprod Biol, in press
  27. Garnett GP, Waddell HC. Public health paradoxes and the epidermiological impact of an HPV vaccine. J Clin Virol 2000; 19: 101-11 https://doi.org/10.1016/S1386-6532(00)00129-3
  28. Harper DM, Franco EL, Wheeler CM, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in preention of infection with human papillomavirsu type 16 and 18 in young women: a randomized controlled trial. Lancet 2004; 364: 1757-65 https://doi.org/10.1016/S0140-6736(04)17398-4
  29. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of bivalent L1 virus-like particle vaccine against human papillomavirus type 16 and 18: follow-up from randomized controlled trial. Lancet 2006; 367: 1247-55 https://doi.org/10.1016/S0140-6736(06)68439-0
  30. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645-51 https://doi.org/10.1056/NEJMoa020586
  31. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylatic quadrivalent human papillomavirus (type 6,11,16 and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-8 https://doi.org/10.1016/S1470-2045(05)70101-7
  32. Dell DL, Chen H, Ahmad F, Stewart DE. Knowledge about human papillomavirus among adolescents. Obstet Gynecol 2000; 96(5 Pt 1): 653-6 https://doi.org/10.1016/S0029-7844(00)01009-7
  33. Moreira ED Jr, de Oliveira BG, Neves RC, Costa S, Karic G, Filho JO. Assessment of knowledge and attitudes of young uninsured women toward human papillomavirus vaccination and clinical trials. J Pediatr Adolesc Gynecol. 2006; 19: 81-7 https://doi.org/10.1016/j.jpag.2006.01.003
  34. Brabin L, Roberts SA, Frazaneh F, Kitchener HC. Future acceptance of adolsent human papillomavirus vaccination: a survey of parental attitudes. Vaccine 2006; 24: 3087-94 https://doi.org/10.1016/j.vaccine.2006.01.048
  35. Lee PW, Kwan TT, Tan KF, Chan KK, Young PM, Lo SS, et al. Beliefs about cervical cancer and human papillomavirus (HPV) and acceptability of HPV vaccination among Chinese women in Hong Kong. Prev Med 2007; 45: 130-4 https://doi.org/10.1016/j.ypmed.2007.07.013
  36. Sauvageau C, Duval B, Gilca V, Lavoie F, Ouakki M. Humam papillomavirus vaccine and cervical cancer screening accerptability among adults in Quecbed, Canada. BMC Public Health 2007; 7: 304 https://doi.org/10.1186/1471-2458-7-304
  37. Lenselink CH, Gerrits MM, Melchers WJ, Massuger LF, van Hamont D, Bekkers RL. Parental acceptance of huma papillomavirus vaccines. Eur J Obstet Gynecol Reprod Biol 2008; 137: 103-7 https://doi.org/10.1016/j.ejogrb.2007.02.012
  38. Taylor JA, Darden PM, Brooks DA, Hendricks JW, Wasserman RC, Bocian AB, et al. Associations between parents' preferences and perpection of barriers to vaccination and immunization status of their children: a study from Pediatric Research in Office Setting and the national Medical Association. Pediatrics 2002; 110: 1110-6 https://doi.org/10.1542/peds.110.6.1110
  39. Marshall H, Ryan P, Roberton D, Baghurst P. A cross-sectional survey to assess community attitude to introduction of Human papillomavirus vaccine. Aust N Z J Publid Health 2007; 31: 235-42 https://doi.org/10.1111/j.1467-842X.2007.00054.x
  40. Food and Drug Administraion. Product approval information-liscensing action. Gardasil(Quadrivalent human papillomavirus type 6,11,16,18) Merk & Co. Whitehouse station, NJ. Available from : URL: http://www.fda.gov/cber/label/HPVmer06086LB. pdf
  41. Davis K, Dickman ED, Ferris D, Dias JK. Human papillomavirus vaccine acceptability among parents of 10-to 15-years-old adolescents. J Low Genit Tract Dis 2004; 8: 188-94 https://doi.org/10.1097/00128360-200407000-00005
  42. Noakes K, Yarwood J, Salisbury D. Parental response to the introducing of a vaccine against human papilloma virus. Hum vaccine 2006; 2: 243-8 https://doi.org/10.4161/hv.2.6.3391